What Is a Therapeutic Vape in Australia? It is not quite as simple as the packaging might imply. Every vape, including nicotine-free products, is subject to strict national controls. Lawful products are supplied through participating pharmacies for quitting smoking or managing nicotine dependence.
That said, pharmacy access does not mean vaping is harmless or right for everyone. Availability, prescription requirements and age limits may also vary between jurisdictions. Professional advice is still important before starting or continuing therapeutic vaping.
Last reviewed: 23 September 2026
Clinical review: This content should be reviewed by an Australian-registered pharmacist, GP or tobacco-treatment specialist before publication.
This information is educational and does not replace personal medical advice, diagnosis or treatment.
1. What Is a Therapeutic Vape in Australia?
A therapeutic vape is a vaping product that is lawfully supplied through a participating pharmacy. It is intended to help with smoking cessation or nicotine-dependence management. Even if it contains no nicotine, it is not treated as an ordinary recreational product.
Therapeutic vaping goods include more than bottles of vape liquid. The category may cover substances, devices, pods, cartridges, accessories, kits and combined packs. Each item must meet the rules that apply to its particular product type.
Australian controls cover both nicotine-containing and nicotine-free vapes. Consumers can only lawfully obtain them through participating pharmacies for an accepted therapeutic purpose. Vape shops, tobacconists, convenience stores and other general retailers cannot legally sell them.
Therapeutic purpose does not equal approval
The term therapeutic refers to a product’s intended use and lawful supply pathway. It does not mean the product is harmless or appropriate for every person. Nor does it mean the Therapeutic Goods Administration has approved it.
Most therapeutic vapes are unapproved therapeutic goods. They do not have the same approval status as medicines registered on the Australian Register of Therapeutic Goods. A pharmacist or prescriber needs to consider whether use is clinically appropriate.
Medicinal cannabis vaporisers are in a separate category. They deliver prescribed medicinal cannabis under different legal and clinical arrangements. The pharmacy rules for therapeutic nicotine vapes should not automatically be applied to medicinal cannabis products.
2. How Australia’s Pharmacy-Only Vape System Works
Australia has a pharmacy-only system for all vape types. A participating pharmacy can supply a product only for smoking cessation or nicotine-dependence management. Recreational retail sales remain unlawful, whether or not the product contains nicotine.
Participation is voluntary, though. Pharmacies are not required to stock or supply therapeutic vapes. Pharmacists, doctors and nurse practitioners are likewise not obliged to recommend, prescribe or dispense them.
Access without a prescription
Adults aged 18 or older may access certain products without a prescription where local law allows it. The product must be nicotine-free or contain no more than 20 mg/mL of nicotine. The pharmacist must also decide that supplying it is clinically appropriate.
This does not mean a person can simply choose a vape from an open retail display. They must first have a consultation with a pharmacist. The pharmacist must also confirm their identity and age before supply.
During that consultation, the pharmacist should assess nicotine use, dependence and earlier quit attempts. They should also consider health conditions, current medicines and possible contraindications. Registered first-line treatments must be discussed, along with suitable dosage and use.
- Proof of age and identity
- An assessment of clinical suitability
- Discussion of approved quitting treatments
- Information about dosage and correct use
- Informed consent before supply
- Smoking or vaping cessation support
The pharmacist must explain that the vape is not registered or listed on the Australian Register of Therapeutic Goods. The patient needs to understand its unapproved status before giving consent. Information about quitting support must also be provided.
Quantity limits and practical availability
Non-prescription supply cannot be more than the amount reasonably needed for one month. A pharmacist may provide that amount only once in a one-month period. These limits discourage bulk buying and allow for regular clinical review.
| Supply route | Prescription requirement | Nicotine limit | Retail legality |
|---|---|---|---|
| Participating pharmacy under pharmacist supervision | Not required for eligible adults where local law permits | Nicotine-free or no more than 20 mg/mL | Lawful only for a therapeutic purpose |
| Participating pharmacy with a valid prescription | Required for higher strengths and some patients or jurisdictions | As clinically prescribed within applicable controls | Lawful when all prescribing and supply requirements are met |
| Vape shop, tobacconist or convenience store | Not applicable | Any concentration | Sale of any vape is unlawful |
| Personal order from an overseas seller | The former personal importation pathway no longer applies | Any concentration | Direct personal importation is unlawful |
3. Prescriptions, Age Rules, Online Sales and Local Laws
Commonwealth rules set the national framework, but state and territory medicines laws still apply. Local laws may add conditions around prescribing, possession, dispensing or supply. As a result, access to the same product can differ across jurisdictional borders.
Some jurisdictions do not allow supply to anyone under 18, even if that person has a prescription. Others may have specific prescribing or dispensing requirements. Families and clinicians should check current local health-department advice before making arrangements.
A prescription from a medical practitioner or nurse practitioner is generally needed for products above 20 mg/mL. It may also be needed where local law does not allow pharmacist-only supply. A prescriber may decide not to prescribe after assessing the patient’s circumstances.
Online orders and overseas products
Pharmacy supply usually involves professional oversight in a pharmacy setting. Ordinary online vape shops cannot offer a lawful alternative. Consumers also cannot use the former personal importation pathway to order vaping goods directly from overseas suppliers.
Authorised businesses may commercially import compliant therapeutic vaping goods, subject to strict customs and therapeutic-goods requirements. That commercial process does not allow personal overseas orders. A foreign website being willing to ship does not make the transaction lawful in Australia.
Not every pharmacy stocks therapeutic vapes, and available stock varies by location. A pharmacy may carry only certain strengths, flavours or device types. Contact a participating pharmacy before travelling, and expect a consultation before any supply.
4. TGA Notification and Therapeutic Vape Product Standards
Most therapeutic vapes are unapproved goods and are not listed on the Australian Register of Therapeutic Goods. The TGA has not individually assessed notified products in the same way as approved medicines. In particular, it has not confirmed every product’s safety, quality, effectiveness or performance.
Instead, a sponsor must notify the TGA before lawful supply can occur. In doing so, the sponsor declares that the product meets the applicable minimum requirements. The product must then appear on the relevant TGA notified vape list.
Notification is not the same as TGA approval or endorsement. It does not show that a vape will help a particular person quit, either. Pharmacists and patients should see the notified list as a regulatory entry point, not a clinical guarantee.
Minimum product requirements
Applicable standards deal with nicotine-content accuracy and permitted ingredients. They also address certain contaminants and unwanted substances. Manufacturers and sponsors must manage toxicological risks linked to the liquid, aerosol and product components.
Device standards cover construction, quality and foreseeable hazards. They include requirements for electrical systems, batteries and design features that influence safe operation. These measures reduce avoidable risks, but they cannot make inhaling vape aerosol risk-free.
- Accurate nicotine concentration and ingredient information
- Controls for prohibited ingredients and contaminants
- Device construction and medical-device quality requirements
- Electrical and battery safety measures
- Toxicological risk assessment and risk management
- Required labels, instructions and information leaflets
- Child-resistant features where the standard requires them
Flavours, names and presentation
Permitted therapeutic vape flavours are limited to mint, menthol and tobacco. Fruit, confectionery and dessert flavours fall outside the lawful therapeutic framework. Mixed flavours, including cherry mint or chocolate mint, are also restricted.
Packaging must have a plain, pharmaceutical-style presentation. Name restrictions limit promotional wording, and decorative branding is controlled. Devices and packaging must not be presented in a way designed to attract young people.
Labels and leaflets must include required warnings, ingredient details and directions where relevant. Instructions must also explain how to use the device or accessory properly. Most importantly, consumers should use only goods supplied through lawful pharmacy pathways.
5. Are Therapeutic Vapes Safer or Effective for Quitting?
Therapeutic vapes are not harmless. Australian guidance does not treat them as first-line treatment for quitting smoking, quitting vaping or managing nicotine dependence. A clinician may still consider them where approved options have not worked or do not appear suitable.
Short-term effects may include throat irritation, coughing, headache, nausea and dizziness. Nicotine may also cause a racing heartbeat, sweating or other dose-related symptoms. It can create or maintain dependence as well.
Liquid nicotine can cause poisoning if swallowed or absorbed through the skin. Children and pets are at particular risk from accidental exposure. Follow storage instructions and seek urgent advice if poisoning is suspected.
Other health and safety concerns
Vaping can expose users to chemicals, fine particles and contaminants in aerosol. Defective or mishandled batteries can overheat, burn or start fires. Damaged devices and incorrect charging may raise those risks.
The long-term effects of repeated aerosol inhalation remain uncertain. Evidence is still developing because products, devices and use patterns continue to change. A lack of decades-long data should never be taken as proof of safety.
- Nicotine dependence and withdrawal
- Poisoning or accidental liquid exposure
- Respiratory irritation and possible lung injury
- Cardiovascular effects, including changes in heart rate
- Battery overheating, burns or fire
- Continued vaping after cigarette use has stopped
Comparing vaping with cigarette smoking
Completely replacing cigarettes with vaping may reduce exposure to some harmful products of tobacco combustion. That lower exposure does not make vaping safe. The comparison also depends on switching completely, rather than vaping only occasionally alongside cigarettes.
Smoking while vaping can preserve substantial smoking-related risk. When a clinician considers therapeutic vaping appropriate, complete cigarette cessation is the intended result. Cutting down by a few cigarettes should not be assumed to remove smoking’s major dangers.
Evidence for quitting
Evidence on vaping for smoking cessation is still evolving. Some research indicates that nicotine vapes can help certain adults stop smoking. Results vary, however, depending on the person, product, nicotine delivery, professional support and treatment adherence.
No notified product comes with a guarantee of success. Findings from trials of selected products also cannot automatically show how every pharmacy product will perform. A clinician should discuss the benefits, uncertainties and alternatives through shared decision-making.
A treatment plan should set a target quit date and include scheduled reviews. It should also provide behavioural support and a plan for cravings or relapse. Where appropriate, the longer-term aim should be to stop therapeutic vaping once cigarette cessation has stabilised.
Individual advice is especially important during pregnancy or breastfeeding. It also matters for people with heart disease, lung conditions, mental health concerns or complex medicine regimens. A clinician should assess nicotine dosage and possible interactions instead of relying on product labels alone.
6. First-Line Quit Options and Professional Support
Behavioural counselling and approved pharmacotherapies remain Australia’s first-line approaches. These treatments have more established evidence and clearer safety information. Combining medicine with tailored support can also improve a person’s chances of quitting.
Nicotine replacement therapy provides nicotine without cigarette smoke. Options include patches, gum, lozenges, oral sprays and inhalers. For example, a clinician may suggest a steady-release patch alongside a faster option for sudden cravings.
- Nicotine patches for steady support
- Gum or lozenges for breakthrough cravings
- Oral sprays for faster nicotine delivery
- Nicotine inhalers for a hand-to-mouth routine
- Combination therapy when clinically appropriate
Approved prescription smoking-cessation medicines may be another option for some adults. Each medicine has contraindications, precautions and possible adverse effects. A doctor can assess suitability without assuming that one medicine works for everyone.
Building a practical quit plan
A pharmacist, doctor or nurse practitioner can assess dependence and previous quit attempts. They can also review pregnancy, health conditions, medicine interactions and personal goals. That assessment can lead to a safer, more realistic plan.
People using therapeutic vapes should pair them with behavioural support rather than relying on the device alone. Follow-up appointments can identify adverse effects, dosage issues or continued smoking. They also create chances to reduce and eventually stop vaping.
Quitline Australia provides free, evidence-based support on 13 7848. Participating pharmacies and general practitioners can also explain the treatment options available. Current government health resources offer further information about quitting smoking and vaping.
Laws, notified products and local access conditions may change. Check current TGA guidance and the relevant state or territory health department before acting. A product that was previously available may be removed from the notified list or no longer be in pharmacy stock.
Conclusion
A therapeutic vape is a tightly regulated pharmacy product intended for smoking cessation or nicotine-dependence management. Access depends on age, nicotine strength, clinical suitability and local law. TGA notification confirms a sponsor’s declared compliance; it is not product approval.
Vaping still carries health risks and is not Australia’s first-line quitting treatment. Speak with a pharmacist, doctor or nurse practitioner about the safest suitable strategy. Free, evidence-based support is also available through Quitline Australia on 13 7848.
